^
    6ms
    Antibody-Drug Conjugates in the Pipeline for Treatment of Melanoma: Target and Pharmacokinetic Considerations. (PubMed, Drugs R D)
    So far, the antibody-drug conjugates have struggled from efficacy problems, with modest effects at best, leading many to be discontinued for melanoma. At the same time, conjugates such as AMT-253, targeting melanoma cell adhesion molecule, and mecbotamab vedotin  targeting AXL receptor tyrosine kinase, are among the most exciting for melanoma treatment in the future.
    PK/PD data • Review • Journal
    |
    AXL (AXL Receptor Tyrosine Kinase) • MCAM (Melanoma Cell Adhesion Molecule)
    |
    mecbotamab vedotin (BA3011) • AMT-253
    9ms
    AMT-253 in Patients With Advanced Solid Tumours (clinicaltrials.gov)
    P1/2, N=96, Recruiting, Multitude Therapeutics Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    AMT-253
    11ms
    AMT-253 in Patients With Advanced Solid Tumours (clinicaltrials.gov)
    P1/2, N=96, Not yet recruiting, Multitude Therapeutics Inc.
    New P1/2 trial • Metastases
    |
    AMT-253
    1year
    A cell surface-binding antibody atlas nominates a MUC18-directed antibody-drug conjugate for targeting melanoma. (PubMed, Cancer Res)
    AMT-253, an MUC18-directed ADC based on topoisomerase I inhibitor exatecan and a self-immolative T moiety, had a higher therapeutic index compared with its microtubule inhibitor-based counterpart and favorable pharmacokinetics and tolerability in monkeys...Beyond melanoma, AMT-253 was also efficacious in a wide range of MUC18-expressing solid tumors. Efficient target/antibody discovery in combination with the T moiety-exatecan linker-payload exemplified here may facilitate discovery of new ADC to improve cancer treatment.
    Journal
    |
    MCAM (Melanoma Cell Adhesion Molecule) • ASAP1 (ArfGAP With SH3 Domain)
    |
    MCAM expression • MUC1 overexpression
    |
    AMT-253
    1year
    AMT-253 in Patients With Selected Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=54, Recruiting, Multitude Therapeutics (Australia) Pty Ltd | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    AMT-253
    over1year
    AMT-253 in Patients With Selected Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=54, Not yet recruiting, Multitude Therapeutics (Australia) Pty Ltd
    New P1 trial • Metastases
    |
    AMT-253